终末期肾病患者难治性高血压致病机制及治疗研究进展
Research Progress on Pathogenesis and Treatment of Refractory Hypertension in Patients with End-Stage Renal Disease
摘要: 高血压是心脑血管疾病的主要危险因素之一，会增加心衰、脑卒中、冠心病等疾病的发生风险。难治性高血压是高血压的一种特殊类型，对于常规降压方案无效或不敏感。该类患者由于血压长期不达标，其心血管事件发生风险远高于一般高血压患者。在终末期肾病患者中由于液体潴留、动脉僵硬度增加、肾脏代谢异常等因素，难治性高血压发生率相对较高。然而目前关于该类患者高血压发生或进展的致病机制尚不明确且常规降压治疗效果欠佳。本文就终末期肾病患者难治性高血压致病机制及治疗策略作简要阐述。
Abstract: Hypertension is one of the main risk factors of cardiovascular and cerebrovascular diseases, which will increase the risk of heart failure, stroke, coronary heart disease and other diseases. Treatment-resistant hypertension is a specific type of high blood pressure that is ineffective or insensitive to conventional blood pressure lowering regiments. Due to long-term substandard blood pressure, the risk of cardiovascular events in these patients is much higher than that in general hypertensive patients. The incidence of refractory hypertension is relatively high in patients with end-stage renal disease due to fluid retention, increased arterial stiffness and abnormal renal metabolism. However, the pathogenesis of hypertension in these patients is still unclear and the effect of conventional antihypertensive therapy is not good. In this paper, the pathogenesis and treatment strategies of refractory hypertension in patients with end-stage renal disease were briefly reviewed.
文章引用：李琴, 杜建霖, 胡蓉. 终末期肾病患者难治性高血压致病机制及治疗研究进展[J]. 临床医学进展, 2025, 15(2): 666-671. https://doi.org/10.12677/acm.2025.152393

参考文献

[1] Wang, L., Xu, X., Zhang, M., Hu, C., Zhang, X., Li, C., et al. (2023) Prevalence of Chronic Kidney Disease in China: Results from the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Internal Medicine, 183, 298-310. [Google Scholar] [CrossRef] [PubMed]
[2] 中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者高血压管理指南(2023年版) [J]. 中华肾脏病杂志, 2023, 39(1): 48-80.
[3] 董一飞, 董徽, 许建忠, 等. 《中国高血压防治指南(2024年修订版)》更新要点解读[J]. 中华高血压杂志(中英文), 2025, 33(1): 14-17.
[4] Agarwal, R., Nissenson, A.R., Batlle, D., Coyne, D.W., Trout, J.R. and Warnock, D.G. (2003) Prevalence, Treatment, and Control of Hypertension in Chronic Hemodialysis Patients in the United States. The American Journal of Medicine, 115, 291-297. [Google Scholar] [CrossRef] [PubMed]
[5] Georgianos, P.I. and Agarwal, R. (2019) Systolic and Diastolic Hypertension among Patients on Hemodialysis: Musings on Volume Overload, Arterial Stiffness, and Erythropoietin. Seminars in Dialysis, 32, 507-512. [Google Scholar] [CrossRef] [PubMed]
[6] Van Biesen, W., Williams, J.D., Covic, A.C., Fan, S., Claes, K., Lichodziejewska-Niemierko, M., et al. (2011) Fluid Status in Peritoneal Dialysis Patients: The European Body Composition Monitoring (EuroBCM) Study Cohort. PLOS ONE, 6, e17148. [Google Scholar] [CrossRef] [PubMed]
[7] Agarwal, R., Alborzi, P., Satyan, S. and Light, R.P. (2009) Dry-weight Reduction in Hypertensive Hemodialysis Patients (Drip). Hypertension, 53, 500-507. [Google Scholar] [CrossRef] [PubMed]
[8] Munoz Mendoza, J., Sun, S., Chertow, G.M., Moran, J., Doss, S. and Schiller, B. (2011) Dialysate Sodium and Sodium Gradient in Maintenance Hemodialysis: A Neglected Sodium Restriction Approach? Nephrology Dialysis Transplantation, 26, 1281-1287. [Google Scholar] [CrossRef] [PubMed]
[9] Bragg-Gresham, J.L., Fissell, R.B., Mason, N.A., Bailie, G.R., Gillespie, B.W., Wizemann, V., et al. (2007) Diuretic Use, Residual Renal Function, and Mortality among Hemodialysis Patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). American Journal of Kidney Diseases, 49, 426-431. [Google Scholar] [CrossRef] [PubMed]
[10] Sibbel, S., Walker, A.G., Colson, C., Tentori, F., Brunelli, S.M. and Flythe, J. (2018) Association of Continuation of Loop Diuretics at Hemodialysis Initiation with Clinical Outcomes. Clinical Journal of the American Society of Nephrology, 14, 95-102. [Google Scholar] [CrossRef] [PubMed]
[11] Georgianos, P.I. and Agarwal, R. (2024) Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management. Journal of the American Society of Nephrology, 35, 505-514. [Google Scholar] [CrossRef] [PubMed]
[12] Sarafidis, P.A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P., Ferro, C., et al. (2017) Hypertension in Dialysis Patients: A Consensus Document by the European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association—European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney Working Group of the European Society of Hypertension (ESH). Journal of Hypertension, 35, 657-676. [Google Scholar] [CrossRef] [PubMed]
[13] Georgianos, P.I. and Agarwal, R. (2015) Aortic Stiffness, Ambulatory Blood Pressure, and Predictors of Response to Antihypertensive Therapy in Hemodialysis: An Integrated Index of Vascular Function? American Journal of Kidney Diseases, 66, 305-312. [Google Scholar] [CrossRef] [PubMed]
[14] Cruickshank, K., Riste, L., Anderson, S.G., Wright, J.S., Dunn, G. and Gosling, R.G. (2002) Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance. Circulation, 106, 2085-2090. [Google Scholar] [CrossRef] [PubMed]
[15] Stabley, J.N. and Towler, D.A. (2017) Arterial Calcification in Diabetes Mellitus: Preclinical Models and Translational Implications. Arteriosclerosis, Thrombosis, and Vascular Biology, 37, 205-217. [Google Scholar] [CrossRef] [PubMed]
[16] Tian, Z. and Liang, M. (2021) Renal Metabolism and Hypertension. Nature Communications, 12, Article No. 963. [Google Scholar] [CrossRef] [PubMed]
[17] Wei, X., Hou, Y., Long, M., Jiang, L. and Du, Y. (2023) Advances in Energy Metabolism in Renal Fibrosis. Life Sciences, 312, Article ID: 121033. [Google Scholar] [CrossRef] [PubMed]
[18] Palm, F. and Nordquist, L. (2011) Renal Oxidative Stress, Oxygenation, and Hypertension. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 301, R1229-R1241. [Google Scholar] [CrossRef] [PubMed]
[19] Camargo, L.L., Rios, F.J., Montezano, A.C. and Touyz, R.M. (2024) Reactive Oxygen Species in Hypertension. Nature Reviews Cardiology, 22, 20-37. [Google Scholar] [CrossRef] [PubMed]
[20] Griendling, K.K., Camargo, L.L., Rios, F.J., Alves-Lopes, R., Montezano, A.C. and Touyz, R.M. (2021) Oxidative Stress and Hypertension. Circulation Research, 128, 993-1020. [Google Scholar] [CrossRef] [PubMed]
[21] Mu, B., Zeng, Y., Luo, L. and Wang, K. (2024) Oxidative Stress-Mediated Protein Sulfenylation in Human Diseases: Past, Present, and Future. Redox Biology, 76, Article ID: 103332. [Google Scholar] [CrossRef] [PubMed]
[22] Xiao, L., Patrick, D.M., Aden, L.A. and Kirabo, A. (2018) Mechanisms of Isolevuglandin-Protein Adduct Formation in Inflammation and Hypertension. Prostaglandins & Other Lipid Mediators, 139, 48-53. [Google Scholar] [CrossRef] [PubMed]
[23] Pinheiro, L.C. (2020) Sources and Effects of Oxidative Stress in Hypertension. Current Hypertension Reviews, 16, 166-180. [Google Scholar] [CrossRef] 
[24] Padovan, J.C., Dourado, T.M.H., Pimenta, G.F., Bruder-Nascimento, T. and Tirapelli, C.R. (2023) Reactive Oxygen Species Are Central Mediators of Vascular Dysfunction and Hypertension Induced by Ethanol Consumption. Antioxidants, 12, Articl e1813. [Google Scholar] [CrossRef] [PubMed]
[25] Azushima, K., Kovalik, J., Yamaji, T., Ching, J., Chng, T.W., Guo, J., et al. (2023) Abnormal Lactate Metabolism Is Linked to Albuminuria and Kidney Injury in Diabetic Nephropathy. Kidney International, 104, 1135-1149. [Google Scholar] [CrossRef] [PubMed]
[26] Qin, Q., Chen, J., Hu, W., Liu, J., Liu, M., Huang, F., et al. (2024) Association of Tricarboxylic Acid Cycle Related-Metabolites with Hypertension in Older Adults: A Community-Based Cross-Sectional Study. Journal of Human Hypertension, 39, 51-57. [Google Scholar] [CrossRef] [PubMed]
[27] Zheng, X., Zhou, L., Jin, Y., Zhao, X., Ahmad, H., OuYang, Y., et al. (2021) β-Aminoisobutyric Acid Supplementation Attenuated Salt-Sensitive Hypertension in Dahl Salt-Sensitive Rats through Prevention of Insufficient Fumarase. Amino Acids, 54, 169-180. [Google Scholar] [CrossRef] [PubMed]
[28] He, W., Miao, F.J., Lin, D.C., Schwandner, R.T., Wang, Z., Gao, J., et al. (2004) Citric Acid Cycle Intermediates as Ligands for Orphan G-Protein-Coupled Receptors. Nature, 429, 188-193. [Google Scholar] [CrossRef] [PubMed]
[29] Agarwal, R. (2017) Mechanisms and Mediators of Hypertension Induced by Erythropoietin and Related Molecules. Nephrology Dialysis Transplantation, 33, 1690-1698. [Google Scholar] [CrossRef] [PubMed]
[30] Symonides, B., Lewandowski, J. and Małyszko, J. (2023) Resistant Hypertension in Dialysis. Nephrology Dialysis Transplantation, 38, 1952-1959. [Google Scholar] [CrossRef] [PubMed]
[31] Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., et al. (2018) 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. European Heart Journal, 39, 3021-3104. [Google Scholar] [CrossRef] [PubMed]
[32] Agarwal, R., Sinha, A.D., Pappas, M.K., Abraham, T.N. and Tegegne, G.G. (2014) Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril: A Randomized Controlled Trial. Nephrology Dialysis Transplantation, 29, 672-681. [Google Scholar] [CrossRef] [PubMed]
[33] (2024) 2023 ESH Guidelines for the Management of Arterial Hypertension the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA): Erratum. Journal of Hypertension, 42, 194.
[34] Wang, B., Wang, G., Ding, X., Tang, H., Zheng, J., Liu, B., et al. (2022) Effects of Sacubitril/valsartan on Resistant Hypertension and Myocardial Work in Hemodialysis Patients. The Journal of Clinical Hypertension, 24, 300-308. [Google Scholar] [CrossRef] [PubMed]
[35] Mahfooz, K., Najeed, S., Tun, H.N., Khamosh, M., Grewal, D., Hussain, A., et al. (2023) New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-analysis. Current Problems in Cardiology, 48, Article ID: 101686. [Google Scholar] [CrossRef] [PubMed]
[36] Schlaich, M.P., Bellet, M., Weber, M.A., Danaietash, P., Bakris, G.L., Flack, J.M., et al. (2022) Dual Endothelin Antagonist Aprocitentan for Resistant Hypertension (PRECISION): A Multicentre, Blinded, Randomised, Parallel-Group, Phase 3 Trial. The Lancet, 400, 1927-1937. [Google Scholar] [CrossRef] [PubMed]
[37] Ye, D., Cruz-López, E.O., Veghel, R.v., Garrelds, I.M., Kasper, A., Wassarman, K., et al. (2024) Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects with Reversir. Hypertension, 81, 1491-1499. [Google Scholar] [CrossRef] [PubMed]
[38] Hoye, N.A., Wilson, L.C., Wilkins, G.T., Jardine, D.L., Putt, T.L., Samaranayaka, A., et al. (2017) Endovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection—A Proof-Of-Concept Study. Kidney International Reports, 2, 856-865. [Google Scholar] [CrossRef] [PubMed]
[39] Scalise, F., Sole, A., Singh, G., Sorropago, A., Sorropago, G., Ballabeni, C., et al. (2020) Renal Denervation in Patients with End-Stage Renal Disease and Resistant Hypertension on Long-Term Haemodialysis. Journal of Hypertension, 38, 936-942. [Google Scholar] [CrossRef] [PubMed]
[40] Scalise, F., Quarti-Trevano, F., Toscano, E., Sorropago, A., Vanoli, J. and Grassi, G. (2024) Renal Denervation in End-Stage Renal Disease: Current Evidence and Perspectives. High Blood Pressure & Cardiovascular Prevention, 31, 7-13. [Google Scholar] [CrossRef] [PubMed]

为你推荐